A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.

Source:http://linkedlifedata.com/resource/pubmed/id/20507881

Download in:

View as

Triples

General Info

PMID
20507881